Spero Therapeutics
Development of novel therapies to treat highly resistant bacterial infections
About Spero
Team
Leadership Team
Board of Directors
Scientific Advisors
Clinical Advisors
Our Science
Pipeline
SPR994: Oral Gram-Negative Program
SPR741 & SPR206: IV Potentiator Platform
SPR720: Oral NTM Program
Key Publications
Our Partners
Antibiotic Resistance
External Resources
News and Events
Press Releases
Spero In The News
Events
ASM Microbe 2016
ASM Microbe 2017
ASM ESCMID 2017
Careers
Contact
Research Laboratory
SPERO NAMED WINNER OF THE
2017 Xconomy Award for Best Startup!
Spero Named One of Boston's
"Best Places To Work in 2017" By the Boston Business Journal!
Spero Named One of Boston's
"Best Places To Work in 2017"
By the Boston Business Journal!
Differentiated pipeline: Unique approaches for the
treatment of highly resistant bacterial infections
Differentiated pipeline: Unique
approaches for the treatment of
highly resistant bacterial infections
Highly experienced team: Over 100 years of experience
and 10 approved anti-infective drugs
Highly experienced team: Over
100 years of experience and 10
approved anti-infective drugs
Cutting edge science: Applying new discoveries
to first-in-class therapeutics
Cutting edge science: Applying
new discoveries to first-in-class
therapeutics
Our Team
About Spero
Spero In The News
Copyright © 2017 Spero Therapeutics | Development of novel therapies to treat highly resistant bacterial infections
by zigzagpress
